Skip to content

Inspection prep notes · Laboratory

Microbiological testing

Also called: sterility test, microbial limits, bioburden, endotoxin

FDA looks less at whether microbiological tests were run than at whether the methods were validated and failing results were investigated on a sound basis. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1An alternative method was not shown to be equivalent to the compendial method

Your firm used the (b)(4) system for (b)(4) microbiological testing of your (b)(4) , raw materials, and finished drug products (e.g., total counts, objectionable microorganisms). However, you failed to demonstrate that this system was equivalent to or better than USP compendial methods and suitable for its intended use.

FDA Warning Letter · Spa De Soleil, Inc. · 2026-07-14 · View document

Your firm outsources your finished drug product sterility testing to a third-party laboratory who performs an ATP-bioluminescent method. Since August 2025, an established method USP <73> has been implemented but you do not have evidence to demonstrate that the laboratory's ATP-bioluminescent method is equivalent to USP <73> ATP bioluminescence-based microbiological methods for the detection of contamination in short-life products.

FDA 483 · LeeSar Inc · 2026-11-05 · View document

2Microbiological test methods were not adequately validated

Your non-compendial test method used to determine microbiological attributes (e.g., total count, objectionable microorganisms) for your finished OTC drug product was inadequate. Specifically, you lacked appropriate incubation times, lacked appropriate method suitability, and lacked positive and negative controls. In addition, you did not validate this non-compendial method.

FDA Warning Letter · Suretec Innovations, LLC · 2026-08-18 · View document

You failed to adequately validate your alternative rapid microbiological test methods.

FDA Warning Letter · Active Cosmetics Manufacturing Inc. · 2026-05-05 · View document

3Sterility test failures were not adequately investigated

You did not adequately investigate a failed sterility test result for your aseptically filled (b)(4) mg/ (b)(4) ml. Your firm identified Ustilago spermophora , a fungi, in (b)(4) medium.

FDA Warning Letter · Jabil Inc. · 2026-09-01 · View document

Specifically, your firm did not investigate sterility failures in biological products manufactured from human umbilical cord tissue.

FDA 483 · Bello Bio LLC · 2026-10-27 · View document

4Failing results were invalidated without scientific justification

Without conducting a Phase II investigation, you concluded there was no risk to the manufacturing process or finished product. You invalidated the sterility result without adequate scientific justification and released this lot in July 2025.

FDA Warning Letter · Baxter International Inc. · 2026-10-20 · View document

Additionally, your (b)(4) Microbial Testing SOP allows retesting following an initial failure. Also, your SOP says that if the retest fails, your analysts are to use the (b)(4) , a second microbiological testing instrument. You routinely invalidated failing batch release results from the (b)(4) system and used the passing (b)(4) results to release product to the market without scientific justification.

FDA Warning Letter · SnugZ USA, Inc. · 2026-10-20 · View document

5Testing of water for objectionable microorganisms was not in place

Specifically, you did not perform adequate testing for objectionable microorganisms in your (b)(4) water (e.g., Burkholderia cepacia complex (BCC)) or sample your manufacturing points-of-use.

FDA Warning Letter · World Perfumes Inc. · 2025-11-18

Specifically, You have not established a written procedure for testing of objectionable organisms in [redacted] water that is used in the production process of APIs that are used for the manufacturing of [redacted] drug products.

FDA 483 · Yuki Gosei Kogyo, Co., Ltd · 2026-11-05 · View document

Questions to check against your procedures

  1. Is there data showing that an alternative microbiological method is equivalent to or better than the compendial method?
  2. Do you hold evidence that the sterility method used by the contract laboratory is equivalent to the compendial method?
  3. Does a non-compendial method define incubation times, method suitability, and positive and negative controls?
  4. Is every sterility test failure investigated?
  5. Is the scientific justification recorded when a microbiological test result is invalidated?
  6. Is there a procedure for testing water for objectionable microorganisms, and are manufacturing points-of-use sampled?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.